Mast cell activation syndrome (MCAS): management
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Mast cell activation syndrome (MCAS): management. Elevated or increasing serum tryptase. Fully referenced neurology checklist.
Biochemical investigations
- Elevated or increasing serum tryptase
- 24-hour urinary histamine metabolites
- 24-hour urinary prostaglandin D2 or its metabolites
Associated non-specific blood tests
Locked: subscribe to see this section.
Magnetic resonance imaging (MRI) brain: features
Locked: subscribe to see this section.
Treatment: acute
Locked: subscribe to see this section.
Treatment: chronic
Locked: subscribe to see this section.
References
- Weiler CR, Austen KF, Akin C, et al. AAAAI Mast Cell Disorders Committee Work Group Report: mast cell activation syndrome (MCAS) diagnosis and management. J Allergy Clin Immunol 2019; 144:883-896.
- Frieri M. Mast cell activation syndrome. Clin Rev Allergy Immunol 2018; 54:353-365.
- Boddaert N, Salvador A, Chandesris MO, et al. Neuroimaging evidence of brain abnormalities in mastocytosis. Transl Psychiatry 2017; 7:e1197.
- Haenisch B, Molderings GJ. White matter abnormalities are also repeatedly present in patients with systemic mast cell activation syndrome. Transl Psychiatry 2018; 8:95.
- Berry R, Hollingsworth P, Lucas M. Successful treatment of idiopathic mast cell activation syndrome with low-dose Omalizumab. Clin Transl Immunology 2019; 8:e01075.
